Arrowhead Pharmaceuticals Receives Hold Rating from Bernstein Analyst

Arrowhead Pharmaceuticals (ARWR) received a Hold rating from Bernstein. The company's shares closed at $20.75. William Pickering from Bernstein maintained the rating, covering the Healthcare sector. Pickering has an average return of -1.1% and a 49.25% success rate on recommended stocks. ARWR has a market cap of $2.75B and a P/E ratio of -15.99.

Arrowhead Pharmaceuticals (ARWR) recently received a Hold rating from Bernstein, with the company's shares closing at $20.75. William Pickering, an analyst at Bernstein covering the Healthcare sector, maintained the rating [2]. The rating comes amidst mixed performance for ARWR, which has underperformed the market in the last year but has shown short-term gains.

The company's market capitalization stands at $2.75 billion, and its P/E ratio is -15.99 [2]. ARWR has been involved in various clinical trials and collaborations, most notably with Sarepta Therapeutics Inc. (NASDAQ:SRPT). Recently, ARWR received $100 million in payments from Sarepta, with $50 million in cash and $50 million in shares redeemed and placed into the treasury [1]. This move reduced the company's outstanding shares, boosting the value of existing shares.

Despite the recent gains, ARWR has faced regulatory setbacks with Sarepta's gene therapy, Elevidys, receiving thumbs down from regulators [2]. Additionally, the company has been actively involved in various clinical trials, including Phase 3 studies for Zodasiran and Plozasiran, and a Phase 1/2a study for ARO-ALK7 [2].

Investors should closely monitor ARWR's ongoing clinical trials and partnerships, as well as any regulatory developments, to assess the company's future prospects. The Hold rating from Bernstein suggests a cautious stance, indicating that the analyst does not see significant upside potential in the near term.

References:

[1] https://finance.yahoo.com/news/arrowhead-arwr-climbs-24-9-163154134.html
[2] https://marketchameleon.com/Overview/ARWR/Summary/